Supplementary materials: Comparative economic outcomes in patients with focal seizures initiating eslicarbazepine acetate versus brivaracetam in the long-term care setting in the USA

These are peer-reviewed supplementary materials for the article 'Comparative economic outcomes in patients with focal seizures initiating eslicarbazepine acetate versus brivaracetam in the long-term care setting in the USA' published in the Journal of Comparative Effectiveness Research.Supplementary Table S1: Sensitivity analysis: Baseline demographics of patients with any epilepsy or seizure diagnosis by ASM cohortSupplementary Table S2: Sensitivity analysis: Baseline demographics of patients with any epilepsy or seizure diagnosis stratified by IDD, by ASM cohortSupplementary Table S3: Sensitivity analysis: Baseline demographics of patients with any epilepsy or seizure diagnosis stratified by age ≥ 65 years, by ASM cohortSupplementary Table S4: Sensitivity analysis: Baseline demographics of patients with any epilepsy or seizure diagnosis stratified by 0–1 prior ASMs, by ASM cohortSupplementary Table S5: Baseline clinical characteristics for patients with any epilepsy or seizure diagnosis by ASM cohort, pre and post-IPTWSupplementary Table S6: Baseline clinical characteristics of patients with any epilepsy or seizure diagnosis stratified by IDD, by ASM cohortSupplementary Table S7: Baseline clinical characteristics for patients with any epilepsy or seizure diagnosis stratified by age ≥ 65 years, by ASM cohortSupplementary Table S8: Baseline clinical characteristics of patients with any epilepsy or seizure diagnosis stratified by 0–1 prior ASMsSupplementary Table S9: All-cause and epilepsy-specific healthcare costs over the post-index period in patients with any epilepsy or seizure diagnosis, by ASM cohortSupplementary Figure S1: Sensitivity analysis: Key inclusion and exclusion criteria for patients with any epilepsy or seizure diagnosisSupplementary Figure S2: Sensitivity analysis: Relative changes for patients with any epilepsy or seizure diagnosis in (A) all-cause and (B) epilepsy-specific pharmacy cost and (C) all-cause and (D) epilepsy-specific total cost during the follow-up period (GLM results post-IPTW)Supplementary Figure S3: Sensitivity analysis: Relative changes for patients with any epilepsy or seizure diagnosis with IDD in (A) all-cause and (B) epilepsy-specific pharmacy cost and (C) all-cause and (D) epilepsy-specific total cost during the follow-up period (GLM results)Supplementary Figure S4: Sensitivity analysis: Relative changes for patients with any epilepsy or seizure diagnosis among patients aged ≥ 65 years in (A) all-cause and (B) epilepsy-specific pharmacy cost and (C) all-cause and (D) epilepsy-specific total cost during the follow-up period (GLM results)Supplementary Figure S5: Sensitivity analysis: Relative changes for patients with any epilepsy or seizure diagnosis among patients with 0–1 prior ASMs (A) all-cause and (B) epilepsy-specific pharmacy cost and (C) all-cause and (D) epilepsy-specific total cost during the follow-up period (GLM results)Aim: To compare all-cause and epilepsy-specific pharmacy and total costs associated with initiation of eslicarbazepine acetate (ESL) or brivaracetam (BRV) among patients with focal seizures in long-term care (LTC) in theUS. Methods: This retrospective analysis used data from IQVIA’s New DataWarehouse. Results: 298 patients initiated ESL and 282 patients initiated BRV. Initiation of ESL versus BRV was associated with 33.3% lower all-cause pharmacy costs, 34.4% lower epilepsy-specific pharmacy costs, 21.3% lower all-cause total costs and 30.9% lower epilepsy-specific total costs (all p < 0.0001). Conclusion: Among patients with focal seizures in LTC in the US, initiation of ESL versus BRV was associated with significant reductions in all-cause and epilepsy-specific pharmacy and total costs compared with initiation of BRV.

本数据集为发表于《比较疗效研究杂志》之文章《在美国长期照护环境中，启动丙戊酸乙酯与溴加兰肽治疗局灶性癫痫发作患者的经济效果比较》的同行评审补充材料。补充表S1：敏感性分析：任何癫痫或癫痫发作诊断患者的基线人口统计学特征，按ASM队列分类；补充表S2：敏感性分析：按IDD分层，任何癫痫或癫痫发作诊断患者的基线人口统计学特征，按ASM队列分类；补充表S3：敏感性分析：按年龄≥65岁分层，任何癫痫或癫痫发作诊断患者的基线人口统计学特征，按ASM队列分类；补充表S4：敏感性分析：按0-1次先前ASM分层，任何癫痫或癫痫发作诊断患者的基线人口统计学特征，按ASM队列分类；补充表S5：按ASM队列分类，任何癫痫或癫痫发作诊断患者的基线临床特征，IPTWS前后的变化；补充表S6：按IDD分层，按ASM队列分类，任何癫痫或癫痫发作诊断患者的基线临床特征；补充表S7：按年龄≥65岁分层，按ASM队列分类，任何癫痫或癫痫发作诊断患者的基线临床特征；补充表S8：按0-1次先前ASM分层，任何癫痫或癫痫发作诊断患者的基线临床特征；补充表S9：任何癫痫或癫痫发作诊断患者在索引期后全因和癫痫特异性的医疗保健成本，按ASM队列分类；补充图S1：敏感性分析：任何癫痫或癫痫发作诊断患者的关键纳入和排除标准；补充图S2：敏感性分析：在随访期间（IPTW后的GLM结果）任何癫痫或癫痫发作诊断患者在（A）全因和（B）癫痫特异性的药品成本以及（C）全因和（D）癫痫特异性的总成本中的相对变化；补充图S3：敏感性分析：在随访期间（GLM结果）具有IDD的任何癫痫或癫痫发作诊断患者在（A）全因和（B）癫痫特异性的药品成本以及（C）全因和（D）癫痫特异性的总成本中的相对变化；补充图S4：敏感性分析：在随访期间（GLM结果）年龄≥65岁的任何癫痫或癫痫发作诊断患者在（A）全因和（B）癫痫特异性的药品成本以及（C）全因和（D）癫痫特异性的总成本中的相对变化；补充图S5：敏感性分析：在随访期间（GLM结果）有0-1次先前ASM的任何癫痫或癫痫发作诊断患者在（A）全因和（B）癫痫特异性的药品成本以及（C）全因和（D）癫痫特异性的总成本中的相对变化。研究目的：比较在美国长期照护环境中，针对局灶性癫痫发作患者启动丙戊酸乙酯（ESL）或溴加兰肽（BRV）所关联的全因及癫痫特异性的药品和总成本。研究方法：此项回顾性分析采用了IQVIA新数据仓库中的数据。研究结果：298名患者启动了ESL，282名患者启动了BRV。与BRV相比，ESL的启动与全因药品成本的33.3%降低、癫痫特异性的药品成本的34.4%降低、全因总成本的21.3%降低以及癫痫特异性的总成本的30.9%降低相关（所有p < 0.0001）。研究结论：在美国长期照护环境中，对于局灶性癫痫发作的患者，与BRV相比，ESL的启动显著降低了全因和癫痫特异性的药品及总成本。